SBI Securities’s AgomAb Therapeutics NV AGMB Stock Holding History
Bought
Maintained
Sold
Other funds holding AGMB
SL
SBI Securities's AGMB Position: Q3 2026 in Review
SBI Securities held its AgomAb Therapeutics NV (AGMB) position steady in Q3 2026 at 2 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #3900.
SBI Securities first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. The position peaked at $26 in Q2 2026. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.
- SBI Securities held 2 shares of AgomAb Therapeutics NV worth $22 as of Q3 2026.
- SBI Securities left its AgomAb Therapeutics NV share count unchanged in Q3 2026.
- AgomAb Therapeutics NV made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3900 holding.
- SBI Securities first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
- SBI Securities's AgomAb Therapeutics NV position peaked at $26 in Q2 2026.
- 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.
Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.